Local Th17/IgA Immunity Correlate with Protection Against Intranasal Infection with Streptococcus Pyogenes

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Apr 18

PMID 28414746

Citations 14

Authors

Rasmus Mortensen

Dennis Christensen

Lasse Bollehuus Hansen

Jan Pravsgaard Christensen

Peter Andersen

Jes Dietrich

Affiliations

Soon will be listed here.

Abstract

Streptococcus pyogenes (group A streptococcus, GAS) is responsible for a wide array of infections. Respiratory transmission via droplets is the most common mode of transmission but it may also infect the host via other routes such as lesions in the skin. To advance the development of a future vaccine against GAS, it is therefore important to investigate how protective immunity is related to the route of vaccine administration. To explore this, we examined whether a parenterally administered anti-GAS vaccine could protect against an intranasal GAS infection or if this would require locally primed immunity. We foundd that a parenteral CAF01 adjuvanted GAS vaccine offered no protection against intranasal infection despite inducing strong systemic Th1/Th17/IgG immunity that efficiently protected against an intraperitoneal GAS infection. However, the same vaccine administered via the intranasal route was able to induce protection against repeated intranasal GAS infections in a murine challenge model. The lack of intranasal protection induced by the parenteral vaccine correlated with a reduced mucosal recall response at the site of infection. Taken together, our results demonstrate that locally primed immunity is important for the defense against intranasal infection with Streptococcus pyogenes.

Citing Articles

Protection acquired upon intraperitoneal group a immunization is independent of concurrent adaptive immune responses but relies on macrophages and IFN-γ.

Emami S, Westerlund E, Converso T, Johansson-Lindbom B, Persson J Virulence. 2025; 16(1):2457957.

PMID: 39921669 PMC: 11810095. DOI: 10.1080/21505594.2025.2457957.

Disruption of IL-17-mediated immunosurveillance in the respiratory mucosa results in invasive infection.

Mills J, Lepletier A, Ozberk V, Dooley J, Kaden J, Calcutt A Front Immunol. 2024; 15:1351777.

PMID: 38576622 PMC: 10991685. DOI: 10.3389/fimmu.2024.1351777.

A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils.

Ozberk V, Zaman M, Lepletier A, Eskandari S, Kaden J, Mills J Nat Commun. 2023; 14(1):5963.

PMID: 37749129 PMC: 10520070. DOI: 10.1038/s41467-023-41410-7.

IgG2 rules: N-acetyl-β-D-glucosamine-specific IgG2 and Th17/Th1 cooperation may promote the pathogenesis of acute rheumatic heart disease and be a biomarker of the autoimmune sequelae of .

Kirvan C, Canini H, Swedo S, Hill H, Veasy G, Jankelow D Front Cardiovasc Med. 2023; 9:919700.

PMID: 36815140 PMC: 9939767. DOI: 10.3389/fcvm.2022.919700.

Correlates of immunity to Group A Streptococcus: a pathway to vaccine development.

Frost H, Excler J, Sriskandan S, Fulurija A NPJ Vaccines. 2023; 8(1):1.

PMID: 36650164 PMC: 9844947. DOI: 10.1038/s41541-022-00593-8.

References

Brandt E, Sriprakash K, Hobb R, Hayman W, Zeng W, Batzloff M . New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med. 2000; 6(4):455-9. DOI: 10.1038/74719. View

Turner D, Farber D . Mucosal resident memory CD4 T cells in protection and immunopathology. Front Immunol. 2014; 5:331. PMC: 4094908. DOI: 10.3389/fimmu.2014.00331. View

Agger E, Rosenkrands I, Hansen J, Brahimi K, Vandahl B, Aagaard C . Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One. 2008; 3(9):e3116. PMC: 2525815. DOI: 10.1371/journal.pone.0003116. View

Mortensen R, Nissen T, Blauenfeldt T, Christensen J, Andersen P, Dietrich J . Adaptive Immunity against Streptococcus pyogenes in Adults Involves Increased IFN-γ and IgG3 Responses Compared with Children. J Immunol. 2015; 195(4):1657-64. DOI: 10.4049/jimmunol.1500804. View

Hall M, Stroop S, Hu M, Walls M, Reddish M, Burt D . Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect Immun. 2004; 72(5):2507-12. PMC: 387888. DOI: 10.1128/IAI.72.5.2507-2512.2004. View

Wang B, Dileepan T, Briscoe S, Hyland K, Kang J, Khoruts A . Induction of TGF-beta1 and TGF-beta1-dependent predominant Th17 differentiation by group A streptococcal infection. Proc Natl Acad Sci U S A. 2010; 107(13):5937-42. PMC: 2851870. DOI: 10.1073/pnas.0904831107. View

Gillen C, Courtney H, Schulze K, Rohde M, Wilson M, Timmer A . Opacity factor activity and epithelial cell binding by the serum opacity factor protein of Streptococcus pyogenes are functionally discrete. J Biol Chem. 2008; 283(10):6359-66. DOI: 10.1074/jbc.M706739200. View

Okamoto S, Tamura Y, Terao Y, Hamada S, Kawabata S . Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice. Vaccine. 2005; 23(40):4852-9. DOI: 10.1016/j.vaccine.2005.02.035. View

DENNY Jr F, PERRY W, Wannamaker L . Type-specific streptococcal antibody. J Clin Invest. 1957; 36(7):1092-100. PMC: 1072695. DOI: 10.1172/JCI103504. View

10.

Costalonga M, Cleary P, Fischer L, Zhao Z . Intranasal bacteria induce Th1 but not Treg or Th2. Mucosal Immunol. 2008; 2(1):85-95. PMC: 4637982. DOI: 10.1038/mi.2008.67. View

11.

Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Wisniewska J, Polubinska A . IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol. 2000; 165(10):5814-21. DOI: 10.4049/jimmunol.165.10.5814. View

12.

Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y . Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta. 2005; 1718(1-2):22-31. DOI: 10.1016/j.bbamem.2005.10.011. View

13.

Miettinen M, Matikainen S, Vuopio-Varkila J, Pirhonen J, Varkila K, Kurimoto M . Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Infect Immun. 1998; 66(12):6058-62. PMC: 108774. DOI: 10.1128/IAI.66.12.6058-6062.1998. View

14.

Bahr G, Yousof A, Behbehani K, Majeed H, Sakkalah S, Souan K . Antibody levels and in vitro lymphoproliferative responses to Streptococcus pyogenes erythrogenic toxin A and mitogen of patients with rheumatic fever. J Clin Microbiol. 1991; 29(9):1789-94. PMC: 270212. DOI: 10.1128/jcm.29.9.1789-1794.1991. View

15.

DAlessandri R, Plotkin G, Kluge R, WITTNER M, FOX E, DORFMAN A . Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis. 1978; 138(6):712-8. DOI: 10.1093/infdis/138.6.712. View

16.

Ma C, Li C, Wang X, Zeng R, Yin X, Feng H . Similar ability of FbaA with M protein to elicit protective immunity against group A streptococcus challenge in mice. Cell Mol Immunol. 2009; 6(1):73-7. PMC: 4002543. DOI: 10.1038/cmi.2009.10. View

17.

Miettinen M, Lehtonen A, Julkunen I, Matikainen S . Lactobacilli and Streptococci activate NF-kappa B and STAT signaling pathways in human macrophages. J Immunol. 2000; 164(7):3733-40. DOI: 10.4049/jimmunol.164.7.3733. View

18.

Lannergard J, Gustafsson M, Waldemarsson J, Norrby-Teglund A, Stalhammar-Carlemalm M, Lindahl G . The Hypervariable region of Streptococcus pyogenes M protein escapes antibody attack by antigenic variation and weak immunogenicity. Cell Host Microbe. 2011; 10(2):147-57. DOI: 10.1016/j.chom.2011.06.011. View

19.

Jaffar Z, Ferrini M, Herritt L, Roberts K . Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. J Immunol. 2009; 182(8):4507-11. PMC: 2740792. DOI: 10.4049/jimmunol.0900237. View

20.

Christensen D, Mortensen R, Rosenkrands I, Dietrich J, Andersen P . Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses. Mucosal Immunol. 2016; 10(1):260-270. DOI: 10.1038/mi.2016.28. View